Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study by Pier M. Mannucci,

Slides:

Advertisements

Similar presentations

Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival by Sandra L. Haberichter,

Advertisements

Hemophilia Management: Joint Bleeds and Prophylaxis.

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,

Increased Clearance Explains the Ultra-Large Multimers in Von Willebrand Disease Type 2M Vicenza; Lessons from Recombinant VWF Vicenza and Modeling of.

Pharmacokinetics of Theophylline in Hepatic Disease

Pattern of inheritance and laboratory findings in von Willebrand disease (VWD). The assays of platelet function include a coagulation assay of factor VIII.

The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation by Fumiaki Banno, Anil K. Chauhan, Koichi Kokame,

Thrombin and fibrinogen γ′ impact clot structure by marked effects on intrafibrillar structure and protofibril packing by Marco M. Domingues, Fraser L.

Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the.

VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13 by Koichi Kokame, Masanori Matsumoto, Yoshihiro.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels by Carina J. M. van Schooten,

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.

by Morgan Craig, Antony R. Humphries, and Michael C. Mackey

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

by Nataliya Melnyk, and Jonathan Harrison

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow by.

Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia by N. Frickhofen, E. Müller, M. Sandherr, T. Binder,

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage by Daphne Stewart, Mansze Kong, Valery Novokhatny, Gary Jesmok, and Victor.

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

von Willebrand factor is a cofactor in complement regulation

Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease by.

Volume 66, Issue 4, Pages (October 2004)

by Peter L. Turecek, Hans Peter Schwarz, and Bernd R. Binder

Cloning, expression, and functional characterization of the von Willebrand factor–cleaving protease (ADAMTS13)‏ by Barbara Plaimauer, Klaus Zimmermann,

Thrombin generation: biochemical possibilities and clinical reality

How we choose factor VIII to treat hemophilia

by Alexander Röth, Andreas Hüttmann, Russell P

Increased frequencies of glutathione S-transferase(GSTM1 and GSTT1) gene deletions in Korean patients with acquired aplastic anemia by Kyung A. Lee, Sun.

by Monica Galli, Luisa Ruggeri, and Tiziano Barbui

Red cells from glutathione peroxidase-1–deficient mice have nearly normal defenses against exogenous peroxides by Robert M. Johnson, Gerard Goyette, Yaddanapudi.

by Kenneth Weinberg, Bruce R. Blazar, John E

Total-Thrombus-Formation Analysis System Using a Microchip Flow Chamber Reflects Bleeding Severity of Patients with Type 1 Von Willebrand Disease. by Kenichi.

Apoptotic Vascular Endothelial Cells Become Procoagulant

Blocking VWF platelet binding to treat TTP

Successful Coronary Artery Bypass in Types 2M and 2N von Willebrand Disease Mathieu Fiore, MD, PhD, Marie Tuffigo, MD, Véronique Cahoreau, MD, Pierre.

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population by Sumithira Vasu,

Evidence Supporting Idarucizumab for the Reversal of Dabigatran

Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets by Maria Nikolova, Jean-Daniel Lelievre, Matthieu.

Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor by Anne F. Riddell,

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery C. Solomon, U. Budde, S. Schneppenheim, E. Czaja,

Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation Jooeun Kang, BA, David M. Zhang, David.

Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott

by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Significant gynecological bleeding in women with low von Willebrand factor levels by Michelle Lavin, Sonia Aguila, Niall Dalton, Margaret Nolan, Mary Byrne,

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

Value stream map: direct observation of the baseline transfer process (OR-PACU-PICU, n = 6 patients). Value stream map: direct observation of the baseline.

Platelet Dysfunction in Outpatients With Left Ventricular Assist Devices Barbara Steinlechner, MD, Martin Dworschak, MD, MBA, Beatrice Birkenberg, MD,

Mean plasma concentrations of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis (duration depicted by box.

Ca2+ infusion rates during all three protocol versions.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Unbound drug concentrations in plasma (dotted) and brain ISF (solid, calculated from recovery and dialysate concentration) following repeated subcutaneous.

Patient Tregs express normal levels of suppression.

Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients by Elena.

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A by Barbara A. Konkle, Oleksandra Stasyshyn,

New concepts for anticoagulant therapy in persons with hemophilia

Presentation transcript:

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study by Pier M. Mannucci, Juan Chediak, Wahid Hanna, John Byrnes, Marlies Ledford, Bruce M. Ewenstein, Anastassios D. Retzios, Barbara A. Kapelan, Richard S. Schwartz, Craig Kessler, and Blood Volume 99(2):450-456 January 15, 2002 ©2002 by American Society of Hematology

SDS agarose electrophoresis VWF multimer analysis of paired lots of A-SD and A-SD/HT.Gels were prepared in 1.7% agarose. SDS agarose electrophoresis VWF multimer analysis of paired lots of A-SD and A-SD/HT.Gels were prepared in 1.7% agarose. Pier M. Mannucci et al. Blood 2002;99:450-456 ©2002 by American Society of Hematology

Median values of plasma levels Median values of plasma levels.VWF:RCof (circles, dash-dot lines) and FVIII:C (triangles, solid lines) (A) and of bleeding times (squares, short dash lines) (B) before and after administration of A-SD (open symbols) and A-SD/HT (closed symbols), 60 IU/kg VW... Median values of plasma levels.VWF:RCof (circles, dash-dot lines) and FVIII:C (triangles, solid lines) (A) and of bleeding times (squares, short dash lines) (B) before and after administration of A-SD (open symbols) and A-SD/HT (closed symbols), 60 IU/kg VWF:RCof, in 11 patients with type 3 VWD. Before treatment, median plasma levels of VWF:RCof, FVIII:C, and VWF:Ag were very low or were below detection, and bleeding times were longer than 30 minutes. Plasma levels shown at baseline reflect the lower limits of detection. Pier M. Mannucci et al. Blood 2002;99:450-456 ©2002 by American Society of Hematology

SDS agarose electrophoresis VWF plasma multimer analysis before and after infusion of A-SD/HT (60 IU/kg VWF:RCof) in a representative patient with type 3 VWD.Gels were prepared in 1.2% agarose. SDS agarose electrophoresis VWF plasma multimer analysis before and after infusion of A-SD/HT (60 IU/kg VWF:RCof) in a representative patient with type 3 VWD.Gels were prepared in 1.2% agarose. Lane 1, normal pooled plasma; lane 2, before infusion; lane 3, 15 minutes after infusion; lanes 4 through 9, 1, 3, 6, 12, 24, and 48 hours after infusion. Increased size in circulating VWF multimers was observed for more than 24 hours after infusion. Pier M. Mannucci et al. Blood 2002;99:450-456 ©2002 by American Society of Hematology